Claire Davies, a shareholder in our FDA Law Group, addresses the upcoming deadline for the FDA's review of Stealth BioTherapeutics' application for elamipretide, a therapy for Barth syndrome. This decision could mark the first treatment for this rare mitochondrial disease or the end for the Massachusetts biotech company.